Capital increase in Lundbeck as a result of employee warrant programme and buy-back of shares to fund Long-Term Incentive scheme

  * Lundbeck increases its share capital by 19,284 shares (0,01% of outstanding
    shares) as a result of employee warrant exercise

H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its
share capital by DKK 96,420 as a consequence of the exercise of employee
warrants.
The increase is affected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following prices per share of nominally DKK 5: 19,284 shares at DKK 115.
Proceeds to the company are approximately DKK 2.2 million (approximately USD
0.4 million). The increase corresponds to approximately 0.01% of the company's
share capital.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares shall give rights to
dividends and other rights in relation to the company as of subscription, i.e.
inter alia full rights to dividends for the financial year 2011. The new shares
will be listed on NASDAQ OMX Copenhagen after registration with the Danish
Commerce and Companies Agency. Lundbeck's current share capital amounts to DKK
980,583,170 and will after the capital increase be DKK 980,679,590. The capital
increase is expected to be finalized shortly.

As communicated in connection with the company's results for the first nine
months of 2010 (3 November 2010), Lundbeck operates with Long-Term Incentive
schemes (LTI) for the executive management and key employees in Denmark and
abroad. To fund the programme Lundbeck will buy the necessary Lundbeck shares in
full compliance with the existing NASDAQ OMX Copenhagen rules regarding trading
with treasury shares and Lundbeck's internal rules.

The number of treasury shares included in the schemes currently amounts to less
than 0.1% of the share capital per scheme. The purchases to fund the programme
will be made as late as possible in order to mirror the final number needed. For
the 2012 and 2013 transfer of shares, the corresponding figures are 89,740 and
94,953 shares, which is equal to approximately DKK 12 million and DKK 13 million
at the present share price.

The schemes are charged continuously to the P&L and the purchase of treasury
shares will have no effect on the P&L.

Financial guidance
The content of this release will have no influence on the Lundbeck Group's
financial guidance for 2011 which was provided on 24 February 2011 in connection
with the release of the financial results for 2010.


Lundbeck contacts

Investors:                           Media:



Palle Holm Olesen                    Mads Kronborg

Chief Specialist, Investor Relations Media Relations Manager

+45 36 43 24 26                      +45 36 43 28 51



Magnus Thorstholm Jensen             Simon Mehl Augustesen

Investor Relations Officer           International Media Specialist

+45 36 43 38 16                      +45 36 43 49 80



Jacob Tolstrup

Vice President

+1 847 282 5713


About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose, Lundbeck is
engaged in the research, development, production, marketing and sale of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2010,
the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.


[HUG#1516075]